HALLE (SAALE), Germany, 29 August 2019 – Vivoryon Therapeutics AG (Euronext Amsterdam: VVY), today announced its financial results for the first six months of 2019 ending June 30. The full interim report is available on the company website (https://www.vivoryon.com/investors-news/financial-information/).
Business development efforts in the first half year 2019 led to the announcement of a strategic collaboration with MorphoSys in July for the development of QPCTL technology in immuno-oncology. Vivoryon entered into an exclusive Option Agreement for an up to EUR 15 million equity commitment.
Comment from Dr. Ulrich Dauer, Chief Executive Officer of Vivoryon Therapeutics:
The last six months stand as a transformative time period for Vivoryon during which the team strategically advanced and repositioned the Company through the achievement of several noteworthy corporate goals including the licensing agreement with MorphoSys for our QPCTL inhibitors in oncology, in addition to the validation of our Alzheimer’s Disease program from the NIH. Having collaborated with the management team to redefine our objectives and the most optimal steps to achieve them, we remain well-positioned to reach the next set of corporate and clinical milestones.
Looking back at the first half of 2019, we strengthened three core elements of the Company: our corporate and financial position, the recognition of our potential in oncology and the validation of our approach in Alzheimer’s Disease.
Starting with the completion of a successful private placement, we enhanced our financial standing and added a consortium of new strategic investors to our shareholder base. On top of this, we rebranded and redefined our position as a company. Our new name, “Vivoryon Therapeutics AG,” highlights our strong commitment to developing a treatment for patients suffering from Alzheimer’s Disease and emphasizes the fresh perspectives and momentum we aim to leverage to efficiently advance the Company.
From a pipeline perspective, we have made quantifiable progress in monetizing the opportunity within our approach in immuno-oncology. This was emphasized by our licensing agreement with MorphoSys, which delivered on our promise to combine our unique portfolio of proprietary small molecule QPCTL inhibitors with a leading antibody technology. In addition to this, we also initiated a research collaboration with the University of Kiel to further uncover the therapeutic potential of our QPCTL inhibitors in cellular cancer models.
In regard to our Alzheimer’s program, we received the approval of a USD 15 million NIH grant intended for a US Phase 2b trial, further validating our differentiated therapeutic approach to this detrimental neurodegenerative disease. Our lead candidate, PQ912, stands out from other treatments in the field, as it inhibits the production of the pyroglutamated form of abeta, a neuro- and synaptotoxic driver of Alzheimer’s initiation and progression. Our aim is to advance the Phase 2b clinical trial in Europe during the first quarter of 2020.
As we enter into the second half of the year, we will continue to finalize preparations for the Alzheimer’s clinical trial, explore the potential of our unique proprietary position in cancer and identify additional opportunities within our discovery and development pipeline of small molecule therapeutics. With our near-term objective focused on securing the required financial runway to meet these goals, we look forward to connecting with potential investors and partners in the global biotechnology industry and sharing our revitalized vision of leveraging our versatile scientific approach to advance drug candidates in complex and large medical need indications.
|In EUR k, unless otherwise stated||Jan. – June 2019||Jan. – June 2018||Jan. – Dec. 2018|
|Earnings, Financial and Net Assets Position|
|Finance income /loss||-15||13||-39|
|Net loss for the period||-3,091||-4,120||-7,737|
|Equity (end of the reporting period)||5,636||4,848||1,230|
|Equity ratio (end of the reporting period) (in %)||60.8||67.6||30.4|
|Balance sheet total (end of the reporting period)||9,269||7,169||4,048|
|Cash flows from operating activities (cum.)||-3,428||-4,092||-6,994|
|Cash flows from operating activities (monthly average)||-571||-682||-583|
|Cash flows from investing activities||-4||471||460|
|Cash flows from financing activities||7,644||0||0|
|Total number of employees (incl. Board of management) (end of the reporting period)||16||14||14|
|Loss per share (basic/diluted) (in EUR)||-0.31||-0.50||-0.94|
|Number of shares issued (end of the reporting period)||12,301||8,208||8,208|
The operating loss for first half of 2019 was reduced by 26% to EUR 3,077k (H1 2018: EUR 4,133k). This was driven by lower research and development expenses of EUR 1,862k (H1 2018: EUR 2,572k) and lower general and administrative of EUR 1,223k (H1 2018: EUR 1,578k).
Consequently, net loss was reduced to EUR 3,091k (H1 2018: EUR 4,120k).
All results are in line with management expectations.
Vivoryon Therapeutics held EUR 7,999k in cash and cash equivalents as of June 30, 2019 (Dec 31, 2018: EUR 3,783k).
The cash flow from financing activities in amount of EUR 7,644k resulted from the successful private placement of new shares that raised EUR 8,187k in gross proceeds, which were offset by the associated transaction costs of EUR 523k.
With 20+ years of unmatched understanding in identifying protein-modifying enzymes that play a critical role in disease initiation and progression, Vivoryon Therapeutics scientific expertise has facilitated the creation of a discovery and development platform for small molecule therapeutics.
Having demonstrated success by developing a novel therapeutic in type 2 diabetes, the Company is advancing their lead candidate, PQ912, in Alzheimer’s Disease and their entire portfolio of QPCT and QPCTL inhibitors in oncology.
PQ912 in Alzheimer’s Disease
PQ912 is a first-in-class inhibitor of the QC enzyme that addresses a very distinct disease pathway and provides a different mode of action in contrast to other available Alzheimer’s Disease programs in development. Positive results from a Phase 2a clinical trial published in June 2017 demonstrated a significant improvement in the synaptic function of PQ912-treated Alzheimer’s patients versus a control group in addition to measurable improvements in the memory performance of patients treated with PQ912, despite the short treatment time of only twelve weeks.
The upcoming Phase 2b European, multicenter study, “SAPHIR,” will be conducted over 56 weeks on average and will test varying doses of PQ912. Trial initiation is anticipated in the first quarter of 2020 with the topline results expected in the second half of 2022.
The SAPHIR clinical trial in Europe is led by Professor Philip Scheltens, Director of the Alzheimer Center VU University Medical Center Amsterdam, NL. A second complementary trial, so called US trial, is in the planning phase and will be run by Professor Howard Feldman, Director of Alzheimer’s Disease Cooperative Study (ADCS), in San Diego, USA. The National Institutes of Health (NIH) is funding, in part, the US Phase 2b core program with an NIH Research Project grant expected to total of USD 15 million over four years.
QPCTL Inhibitors in Oncology and Beyond
Recently published results as well as internal research have shown that the Glutaminyl-peptide cyclotransferase-like (QPCTL) is an interesting therapeutic target to silence the “do not eat me” signal provided by the interaction of CD47 (expressed on cancer cells), with the protein SIRP-alpha (expressed on macrophages and other myeloid cells). Tumor immunotherapy that targets this interaction is a current focus of innovation in cancer drug development. Combining a therapeutic tumor-targeted antibody of choice with the inhibition of the CD47/SIRP-alpha interaction is expected to lead to significant therapeutic improvements. By possessing the broadest portfolio of small molecule QPCTL inhibitors and the clinically most advanced compounds in that field, Vivoryon is uniquely positioned to address this attractive target in immuno-oncology. QPCTL inhibitors are expected to have considerable therapeutic advantages compared to antibody approaches that are currently explored in clinical studies to silence the CD47/SIRP-alpha interactions.
Based on Vivoryon Therapeutics’ data, PQ912 could be advanced into clinical Phase I studies in cancer. In addition, the Company entered into an exclusive Option Agreement with MorphoSys on small molecule inhibitors of QPCTL, silencing the CD47-SIRP alpha signaling in immuno-oncology. Vivoryon Therapeutics owns a broader set of highly promising QPCTL inhibitor compounds in advanced preclinical stages of development.
Within the collaboration of the University of Kiel, Vivoryon Therapeutics will also fund focused research with the clear goal of further validating its QPCTL inhibitors in cellular cancer models. The Company’s highly active compounds will be tested individually and in combination with therapeutic antibodies.
Vivoryon Therapeutics will host a conference call and webcast open to the public today, August 29, 2019 at 3:00 pm CEST / 09:00 am EST; the presentation will also be available on the company website. The conference will be held in English. A question & Answer session will follow the presentation of the Half year results.
To participate in the conference call, please call one of the following numbers 10 minutes prior to commencement.
A live webcast and slides will be made available at: www.vivoryon.com/investors-news/financial-information/
Approximately a day after the call, a slide-synchronized audio replay of the conference will be available on: www.vivoryon.com/investors-news/financial-information/
Please dial one of the following access numbers, then enter your PIN Code: 67470409#
A Question & Answer session will follow the presentation of results.
|UK||08002794054||+44 203 009 2470|
|USA||N/A||+1 877 423 0830|
Vivoryon Therapeutics has finalized its financial statements for the first six months of 2019 according to German GAAP (“HGB”) and IFRS. The auditor, KPMG, has reviewed the IFRS statements. The reports are available on the company website (https://www.vivoryon.com/investors-news/financial-information/).
November 28, 2019 Interim Management Statement Q3 2019
For more information, please contact:
Vivoryon Therapeutics AG
Dr. Ulrich Dauer, CEO
MC Services AG
Anne Hennecke, Susanne Kutter
Tel: +49 (0) 211 529 252 27
Notes to Editors:
About Vivoryon Therapeutics AG
With 20+ years of unmatched understanding in identifying protein-modifying enzymes that play a critical role in disease initiation and progression, Vivoryon’s scientific expertise has facilitated the creation of a discovery and development platform for small molecule therapeutics. Having demonstrated success by developing a novel therapeutic in type 2 diabetes, the Company is advancing their lead candidate, PQ912, in Alzheimer’s Disease and their entire portfolio of QPCT and QPCTL inhibitors in oncology.
About Alzheimer’s Disease
Alzheimer’s Disease is a neurological disorder, which is the most common form of dementia. Today, 50 million people are estimated to live with dementia worldwide, and this number is projected to triple to more than 152 million by 2050. Alzheimer’s has an estimated global societal cost of USD 1 trillion. (World Alzheimer Report 2018).
Cancer Immune Checkpoint Inhibitors
Checkpoint inhibitor therapy is a novel kind of cancer immunotherapy. This therapy targets key regulators of the immune system that stimulate or inhibit its actions, which tumors commonly use to protect themselves from attacks by the immune system. QPCTL inhibitor therapy can silence inhibitory cancer checkpoints and thereby restore beneficial immune system functions.
Forward Looking Statements
Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgment of Vivoryon Therapeutics AG as of the date of this press release. Such forward-looking statements are neither promises nor guarantees but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.